Change in formulation and its potential clinical and pharmacoeconomic value: example of extended release venlafaxine

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.5, 2009-05, pp. : 1089-1094

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of extended-release niacin in clinical practice

By Suryadevara Ramya S Karas Richard H Kuvin Jeffrey T

Future Lipidology, Vol. 3, Iss. 1, 2008-02 ,pp. : 9-16

Future Medicine

Access to resources Recommend Favorite

Clinical application of extended-release hydromorphone for pain management

By Grider Jay S

Therapy, Vol. 6, Iss. 5, 2009-09 ,pp. : 653-656

Future Medicine

Access to resources Recommend Favorite

Dosage, titration, and gaps in treatment with extended release niacin in clinical practice

By Kamal-Bahl Sachin J. Burke Thomas A. Watson Douglas J. Wentworth Charles E.

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1817-1821

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis

By Weir Scott Torkin Risa Henney III Herbert R.

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1627-1636

Informa Healthcare

Access to resources Recommend Favorite

An Example on the Value of Non-Randomisation in Clinical Trials in Complementary Medicine

Forschende Komplementärmedizin / Research in Complementary Medicine, Vol. 9, Iss. 2, 2004-11 ,pp. : 105-109

Karger

Access to resources Recommend Favorite